- Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
-
Suzuki H, Tsutsumi T, Kawaguchi M, Amano K, Kawaguchi T
- KMID: 2557402
- Clin Mol Hepatol.
- 2024 Jul;30(3):577-579.
- doi: 10.3350/cmh.2024.0157
-
- CITED
-
- Close
- SHARE
-
- Close
- Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
-
Suzuki H, Tsutsumi T, Kawaguchi M, Amano K, Kawaguchi T
- KMID: 2560097
- Clin Mol Hepatol.
- 2024 Oct;30(4):962-964.
- doi: 10.3350/cmh.2024.0264
-
- CITED
-
- Close
- SHARE
-
- Close
- Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
-
Tsutsumi T, Nakano D, Kawaguchi M, Takahashi H, Kawaguchi T
- KMID: 2554432
- Clin Mol Hepatol.
- 2024 Apr;30(2):266-268.
- doi: 10.3350/cmh.2024.0028
-
- CITED
-
- Close
- SHARE
-
- Close
- Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs
-
Takamura S, Teraki Y, Katayama E, Kawaguchi T, Kawaguchi M, Nakano D, Tsutsumi T, Nagoshi S, Nakama T, Torimura T
- KMID: 2528257
- Clin Mol Hepatol.
- 2022 Apr;28(2):269-272.
- doi: 10.3350/cmh.2022.0040
-
- CITED
-
- Close
- SHARE
-
- Close
- Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia
-
Fukunaga S, Nakane T, Mukasa M, Takedatsu H, Kawaguchi T
- KMID: 2560096
- Clin Mol Hepatol.
- 2024 Oct;30(4):959-961.
- doi: 10.3350/cmh.2024.0233
-
- CITED
-
- Close
- SHARE
-
- Close
- Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD
-
Suzuki H, Shimose S, Iwamoto H, Niizeki T, Kawaguchi T
- KMID: 2554431
- Clin Mol Hepatol.
- 2024 Apr;30(2):263-265.
- doi: 10.3350/cmh.2023.0557
-
- CITED
-
- Close
- SHARE
-
- Close
- Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis
-
Kawaguchi T, Torimura T
- KMID: 2528246
- Clin Mol Hepatol.
- 2022 Apr;28(2):177-180.
- doi: 10.3350/cmh.2021.0246
-
- CITED
-
- Close
- SHARE
-
- Close
- Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD
-
Fukunaga S, Mukasa M, Nakano D, Tsutsumi T, Kawaguchi T
- KMID: 2549391
- Clin Mol Hepatol.
- 2024 Jan;30(1):121-123.
- doi: 10.3350/cmh.2023.0437
-
- CITED
-
- Close
- SHARE
-
- Close
- Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”
-
Nakamura T, Nakano M, Tsutsumi T, Amano K, Kawaguchi T
- KMID: 2560076
- Clin Mol Hepatol.
- 2024 Oct;30(4):705-708.
- doi: 10.3350/cmh.2024.0372
-
- CITED
-
- Close
- SHARE
-
- Close
- Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma
-
Shimose S, Koya S, Kawaguchi T, Hirota K, Yoshio S, Niizeki T, Matsuse H, Torimura T
- KMID: 2520844
- Clin Mol Hepatol.
- 2021 Oct;27(4):616-619.
- doi: 10.3350/cmh.2021.0258
-
- CITED
-
- Close
- SHARE
-
- Close
- Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
-
Koga H, Iwamoto H, Suzuki H, Shimose S, Nakano M, Kawaguchi T
- KMID: 2541403
- Clin Mol Hepatol.
- 2023 Apr;29(2):242-251.
- doi: 10.3350/cmh.2023.0102
Striking advances in systemic therapy for unresectable advanced hepatocellular carcinoma (HCC) have improved the average prognosis of patients with HCC. As a result, the guidelines for the treatment of HCC... -
- CITED
-
- Close
- SHARE
-
- Close
- MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
-
Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J, Torimura T
- KMID: 2528243
- Clin Mol Hepatol.
- 2022 Apr;28(2):150-163.
- doi: 10.3350/cmh.2021.0310
Fatty liver is now a major cause of liver disease in the Asia-Pacific region. Liver diseases in this region have distinctive characteristics. First, fatty liver is frequently observed in lean/normal-weight... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk of venous thromboembolism with a central venous catheter in hospitalized Japanese patients with inflammatory bowel disease: a propensity score-matched cohort study
-
Aoki Y, Kiyohara H, Mikami Y, Nanki K, Kawaguchi T, Yoshimatsu Y, Sugimoto S, Sujino T, Takabayashi K, Hosoe N, Ogata H, Iwao Y, Kanai T
- KMID: 2544755
- Intest Res.
- 2023 Jul;21(3):318-327.
- doi: 10.5217/ir.2022.00116
Background/Aims: Thromboprophylaxis is recommended for hospitalized patients with inflammatory bowel disease (IBD) in Western countries, although it is selectively administered to high-risk patients in East Asia. A central venous catheter... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
-
Iwaki M, Fujii H, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)
- KMID: 2554428
- Clin Mol Hepatol.
- 2024 Apr;30(2):225-234.
- doi: 10.3350/cmh.2023.0515
Background/Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) was recently proposed as an alternative disease concept to nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the prognosis of patients with... -
- CITED
-
- Close
- SHARE
-
- Close
